Innovative Immunomodulatory Antiviral Therapeutics

Jireh BioPath is developing first-in-class small-molecule immunomodulators targeting the innate immune sensor ZBP1. Unlike conventional antivirals that directly target viruses, our pipeline is based on a Host-Directed Therapy (HDT) strategy that precisely modulates innate immunity to control excessive inflammation while preserving protective immune function.

Program
Target
Indication
Modality
  • Discovery
  • Lead Optimization
  • Preclinical
  • Clinical
JBP-101
ZBP1
Broad-Spectrum Antiviral Therapeutic
Small Molecule
Lead Optimization
JBP-201
ZBP1
Alcohol-Associated Liver Disease (ALD)
Small Molecule
Lead Optimization
JBP-301
Innate Immunity Platform
Emerging &
Re-emerging Infectious Diseases
Platform Technology
Discovery
PROGRAM 01

JBP-101

Broad-Spectrum Antiviral Therapeutic

Broad-Spectrum Antiviral Therapeutic Based on Host-Directed Therapy

Target ZBP1
Indication COVID-19, Influenza, HSV, Monkeypox and Emerging or Re-emerging Viral Diseases
Development Stage Lead Optimization
Discovery Lead Optimization Preclinical Clinical
PROGRAM 02

JBP-201

Therapeutic for Alcohol-Associated Liver Disease

An immunomodulatory therapy designed to selectively control pathological inflammation

Target ZBP1
Indication Alcoholic Liver Disease (ALD)
Development Stage Lead Optimization
Discovery Lead Optimization Preclinical Clinical
PROGRAM 03

JBP-301

A Platform Technology with the Potential to Expand into Infectious and Diverse Inflammatory Diseases

Target Next-Generation Innate Immunity Platform
Indication Emerging & Re-emerging Infectious Diseases
Development Stage Discovery
Discovery Lead Optimization Preclinical Clinical